Neurophysiology

Dr. Robert Moghim to Participate in Clinical Trial for Knee Pain Using Freedom Peripheral Nerve Stimulator

Retrieved on: 
Thursday, July 15, 2021

DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.

Key Points: 
  • DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.
  • This study is designed to assess the effectiveness of the Freedom Peripheral Nerve Stimulator (PNS) System for treating chronic knee pain caused by osteoarthritis.
  • Dr. Moghim will be enrolling 10 participants for this study that is expected to last 2 years.
  • The results are intended to help people with arthritic knee pain in the future.

Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021

Retrieved on: 
Wednesday, July 14, 2021

ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes.

Key Points: 
  • ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes.
  • Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m.
  • Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Neosensory partners with Oaktree Products to distribute new tinnitus program, Neosensory Duo, to US audiologists

Retrieved on: 
Tuesday, July 13, 2021

Neosensory has been developing innovative hearing and sensory augmentation solutions since 2015 and was recently recognized by Fast Company's 2021 World Changing Ideas Awards.

Key Points: 
  • Neosensory has been developing innovative hearing and sensory augmentation solutions since 2015 and was recently recognized by Fast Company's 2021 World Changing Ideas Awards.
  • This proprietary, non-invasive method known as bimodal stimulation leverages neuroplasticity and has been shown to reduce tinnitus symptoms in more than 87% of users.
  • For more information about Neosensory and its products, contact Neosensory at [email protected] or visit https://neosensory.com .
  • The company's tinnitus program, Neosensory Duo, launched in March 2021, is based on new scientific research on bimodal stimulation.

Groundbreaking Study Establishes Non-Surgical Treatment Modality to Improve Function in Children With Cerebral Palsy

Retrieved on: 
Tuesday, July 13, 2021

Transcutaneous Spinal Neuromodulation Reorganizes Neural Networks in Patients with Cerebral Palsy discusses how spinal neuromodulation and activity-based rehabilitation triggers neural network reorganization and enhances sensory-motor performances involving the lower limbs, the trunk and the upper limbs.

Key Points: 
  • Transcutaneous Spinal Neuromodulation Reorganizes Neural Networks in Patients with Cerebral Palsy discusses how spinal neuromodulation and activity-based rehabilitation triggers neural network reorganization and enhances sensory-motor performances involving the lower limbs, the trunk and the upper limbs.
  • Cerebral palsy affects over 17 million individuals worldwide and is the most common motor disability in childhood.
  • This study demonstrates dramatic effects of neurostimulation on children with CP.
  • We saw a considerable improvement in head and trunk strength with the very first use of SCONE, said Dawn Hamilton.

MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Retrieved on: 
Tuesday, July 13, 2021

The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).

Key Points: 
  • The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
  • Because Deep TMS penetrates deeper and broader in the brain than traditional TMS, there is evidence that response rates are higher than traditional TMS.
  • For more information regarding Deep TMS services at MindPath Care Centers, visit www.mindpathcare.com/TMS or call the clinic at 877-876-3783.
  • Community Psychiatry and MindPath Care Centers have combined to expand patient access to high-quality, evidence-based, outpatient mental health care across the United States.

CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors

Retrieved on: 
Monday, July 12, 2021

With more than three decades of experience as a business leader in the life science industry, Shadan brings a long track record of success in helping to commercialize medtech innovations for both start-up and large companies.

Key Points: 
  • With more than three decades of experience as a business leader in the life science industry, Shadan brings a long track record of success in helping to commercialize medtech innovations for both start-up and large companies.
  • Prior to joining Rotation Medical, Shadan was the president of the Trauma Division at Zimmer, where she managed the P&L for the global business.
  • I am honored to serve on the CVRx board, says Shadan.
  • CVRx is dedicated to improving patient outcomes, quality of life, and overall cardiovascular health via novel baroreceptor neuromodulation therapies.

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Retrieved on: 
Friday, July 9, 2021

BOSTON, July 8, 2021 /PRNewswire/ --Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.

Key Points: 
  • BOSTON, July 8, 2021 /PRNewswire/ --Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.
  • Beacon Biosignals' EEG neurobiomarker platform is engineered to discover and scale new clinical paradigms for patients with neurological and psychiatric disease.
  • Beacon Biosignals and Cyclerion previously collaborated on the analysis of data from a Cyclerion clinical translational pharmacology study of CY6463 which demonstrated clear effects on EEG parameters associated with aging and disease.
  • For more information about Beacon Biosignals, please visit https://beacon.bio/ and follow us on Twitter (@biosignals) and LinkedIn ( https://www.linkedin.com/company/beacon-biosignals ).

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Retrieved on: 
Thursday, July 8, 2021

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.

Key Points: 
  • CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.
  • Beacon Biosignals EEG neurobiomarker platform is engineered to discover and scale new clinical paradigms for patients with neurological and psychiatric disease.
  • Beacon Biosignals and Cyclerion previously collaborated on the analysis of data from a Cyclerion clinical translational pharmacology study of CY6463 which demonstrated clear effects on EEG parameters associated with aging and disease.
  • For more information about Beacon Biosignals, please visit https://beacon.bio/ and follow us on Twitter (@biosignals) and LinkedIn (https://www.linkedin.com/company/beacon-biosignals).

Researchers Image an Entire Mouse Brain for the First Time

Retrieved on: 
Thursday, July 8, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210708005904/en/
    A team of scientists with Argonne and UChicago visualized an entire mouse brain from synapses on up.
  • Above, a visualization of whole brain interconnectivity, with colors depicting directionality.
  • Using X-ray tomography, researchers were able to image the entire mouse brain roughly one cubic centimeter at the resolution of a micron.
  • But also, the mouse is the workhorse of neuroscience; theyre very useful for analyzing different experimental conditions in the brain.

NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease

Retrieved on: 
Thursday, July 8, 2021

Aarhus University and The Ohio State University are world-leading institutions in neuromuscular disease research.

Key Points: 
  • Aarhus University and The Ohio State University are world-leading institutions in neuromuscular disease research.
  • The primary aim of this study is to discover whether patients with CMT have neuromuscular junction (NMJ) transmission deficits.
  • The hypothesis for the study is that if patients with CMT are found to have deficits in NMJ transmission, then the novel treatment approach being developed by NMD Pharma could potentially have beneficial clinical effects on neuromuscular performance in these patients.
  • NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel.